Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Heidelberg University · University Hospital Heidelberg · +2 more institutions
Abstract
PURPOSE: The prognostic value of genetic alterations characteristic of glioblastoma in patients treated according to present standards of care is unclear. PATIENTS AND METHODS: Three hundred one patients with glioblastoma were prospectively recruited between October 2004 and December 2006 at the clinical centers of the German Glioma Network. Two hundred fifty-eight patients had radiotherapy, 199 patients had temozolomide, 189 had both, and seven had another chemotherapy as the initial treatment. The tumors were investigated for TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor, cyclin-dependent kinase CDK 4 or murine double minute 2 amplification, CDKN2A homozygous deletion, allelic losses…
Citation impact
- FWCI
- 26.93
- Percentile
- 100%
- References
- 34
Authors
18- MWMichael WellerCorresponding
Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- JFJörg Felsberg
Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- CHChristian Hartmann
Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- HBHilmar Berger
Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- JPJoachim P. Steinbach
Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
Topics & keywords
- Temozolomide
- Medicine
- Internal medicine
- IDH1
- Oncology
- Glioma
- Progression-free survival
- CDKN2A
- Good health and well-being